Launch of Refreshed Innovative Licensing and Access Pathway (ILAP)

Full details have now been published on the refreshed UK-wide Innovative Licensing and Access Pathway (ILAP), that will offer a clearer, more streamlined and integrated process for developers to help get transformative new clinically and cost-effective medicines to patients in the National Health Service (NHS) in the shortest time possible.

The new ILAP has been launched by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Technology Appraisal Bodies (the All Wales Therapeutics and Toxicology Centre (AWTTC), the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the NHS.

It is the only example globally of an end-to-end access pathway, where a medicine developer can work collaboratively with the national health system, the regulator, and health technology assessment bodies from the early stages of clinical development.

 Dr Scott Muir, SMC Chair said: 

“SMC is pleased to be an active participant in ILAP, representing the NHS in Scotland. 

“We will continue to work together with our ILAP partners to enable clinically and cost effective, new and innovative medicines to reach patients more quickly.”

Application guidance and further information is available here: Innovative Licensing and Access Pathway (ILAP) - GOV.UK